Mitsui Chemicals, Inc. (4183.T) - Deep Dive Research Report

Sector: Basic Materials (Diversified / Specialty Chemicals) | Listing: Tokyo Stock Exchange Prime, ticker 4183 | Report date: 2026-06-21

Reporting note: Mitsui Chemicals labels the fiscal year ended 31 March 2026 as "FY2025." The six most recent reporting periods used throughout this report are Q3 FY2024 (4 Feb 2025), FY2024 full year (13 May 2025), Q1 FY2025 (7 Aug 2025), Q2/H1 FY2025 (11 Nov 2025), Q3 FY2025 (5 Feb 2026), and FY2025 full year (13 May 2026, conference-call materials dated 28 May 2026). The most recent of these is 39 days before this report date.

Section 1: What the Company Does

Mitsui Chemicals makes the chemical building blocks and finished functional materials that go into things most people never think about but use constantly: the plastic lenses in a pair of glasses, the soft rubber that makes a car bumper flexible, the thin protective film that shields a semiconductor photomask inside the world's most advanced chip factories, the nonwoven fabric in a baby's diaper, and the bulk plastics that become packaging and pipes. It is one of Japan's large integrated chemical companies, and it operates across the full width of the industry, from a naphtha cracker that splits crude-oil derivatives into ethylene and propylene at one end, to nanometre-scale carbon-nanotube films sold to chipmakers at the other.

The company in its current form dates to 1997, when two old Mitsui-lineage chemical firms, Mitsui Petrochemical Industries (founded 1955, the petrochemicals and polyolefins side) and Mitsui Toatsu Chemicals (whose roots run back to early-20th-century fertiliser and industrial chemistry), merged. That history matters because it explains the company's split personality today. One half is a classic, capital-heavy, cyclical commodity-petrochemicals business that lives and dies on the spread between naphtha cost and the price of ethylene and polyolefins. The other half is a portfolio of high-margin specialty materials where Mitsui holds genuine global leadership positions. The entire strategic story of the company over the last decade, and the reason it is interesting right now, is the deliberate, public effort to shrink the first half and grow the second.

The core value proposition differs by product, but the pattern repeats: Mitsui sells materials where decades of accumulated process chemistry, customer qualification, and scale create a position that is hard to dislodge. The clearest example is eyeglass lenses. Mitsui's MR series of high-refractive-index lens monomers is the de facto global standard for thin, lightweight prescription lenses. When you buy "thin lenses" at an optician, the resin was very likely made to Mitsui's chemistry. Lens makers around the world build their products around these monomers, qualify their coating and casting lines to them, and market the refractive index (1.60, 1.67, 1.74) that Mitsui's chemistry enables. Switching monomer suppliers would mean requalifying an entire product family, which is exactly the kind of friction that lets a materials supplier hold share for years.

Under its long-range plan, VISION 2030, management has framed the whole company around a single ambition.

"To become a high-growth, high-profitability global specialty company" - VISION 2030 long-term business plan (formulated June 2021).

The most consequential expression of that ambition came in May 2025, when the company announced it is studying spinning off its entire Basic & Green Materials business - the commodity petrochemicals engine - by around the end of fiscal 2027. If executed, Mitsui Chemicals would transform from a diversified chemical maker into something much closer to a pure specialty-materials company, with the cyclical petrochemical operations housed in a separate vehicle that can be restructured, partnered, or consolidated with rivals on its own timeline.

Section 2: Business Segments

Mitsui Chemicals reports in four domains: three "growth" / specialty domains (Life & Healthcare Solutions, Mobility Solutions, ICT Solutions) plus the commodity domain (Basic & Green Materials). The three specialty domains generate essentially all of the group's operating profit; the commodity domain has recently been loss-making and is the candidate for spin-off.

Life & Healthcare Solutions

This domain covers vision care (eyeglass-lens monomers), oral care materials (dental resins and related products), nonwoven fabrics (for hygiene products such as diapers and masks), personal care ingredients, and agrochemicals (crop-protection actives and formulations).

The core capability is the MR vision-care franchise. Mitsui holds the leading global position in high-refractive-index ophthalmic-lens monomers, a position built over decades of monomer chemistry and customer qualification. The agrochemicals business adds a second leg of specialty chemistry with its own regulatory-approval moat, and the nonwovens business was expanded through integration of operations to gain scale. On recent calls, management described vision care and agrochemicals as volume-growth drivers, while flagging a temporary drag from a production suspension at its Omuta Works (Q2 FY2025 call, 11 Nov 2025).

Why it exists as a distinct domain: the end markets (eyewear, dental, hygiene, agriculture) and the regulatory environments (medical-device-adjacent, agrochemical registration) are completely different from automotive or semiconductors. This is one of the group's steadier profit contributors, less tied to the industrial cycle than Mobility and less tied to the semiconductor cycle than ICT. Management treats it as a stable cash-and-growth domain.

Mobility Solutions

This domain serves the automotive and industrial-products markets with elastomers (notably the TAFMER family of olefin elastomers used to toughen and flexibilise plastics), functional compounds, and polypropylene compounds (the engineering plastics that become bumpers, interior trim, and under-hood parts).

The core capability is polyolefin and elastomer formulation - knowing how to compound resins so they meet automakers' specifications for impact resistance, weight, and processability. Auto-parts qualification is slow and sticky, so once a compound is designed into a vehicle platform it tends to stay for the model's life. Management has pointed to elastomer capacity expansion driving volume growth (a roughly ¥6 billion volume tailwind cited on the Q2 FY2025 call), partly offset by adverse currency and by US trade-policy effects on automotive supply chains.

Why it exists separately: the customer base is the global automotive industry and its tier suppliers, a distinct sales motion with long design-in cycles. Management talks about this as a growth domain leveraged to vehicle electrification and lightweighting, though it carries direct exposure to auto-production volumes and to tariffs.

ICT Solutions

This is the domain that has changed the investment narrative most. It sells semiconductor and electronic-component process materials, optical materials, and lithium-ion and next-generation battery materials. Its two crown-jewel products are EUV pellicles (the protective membrane that sits over a photomask in extreme-ultraviolet lithography) and ICROS tape (a back-grinding tape used in wafer thinning).

The core capability here is unique. Mitsui Chemicals became the world's first commercial EUV pellicle manufacturer, producing under an exclusive license to ASML's design and technology at its Iwakuni-Ohtake Works, with commercial production starting in 2021. EUV pellicles are extraordinarily hard to make: the membrane must transmit ~90% of EUV light, survive the intense energy of a high-power EUV source, and remain defect-free at nanometre scale. The company is now industrialising next-generation carbon-nanotube (CNT) pellicles, in partnership with imec, aimed at the higher-power EUV systems coming into leading-edge fabs. Management has repeatedly cited semiconductor-demand recovery driving volume gains in pellicles and ICROS tape for cutting-edge applications (Q2 FY2025, 11 Nov 2025; Q3 FY2025, 5 Feb 2026).

Why it exists separately: this is the highest-growth, highest-strategic-optionality domain, tied to the global semiconductor capex cycle rather than to autos or consumer staples. Management treats ICT as the growth bet and the showcase for the specialty pivot, and the specialty domains as a group were described as holding operating margins "in the 11% range" (Q2 FY2025 call, 11 Nov 2025).

Basic & Green Materials (B&GM)

This is the commodity engine: ethylene, propylene, polyethylene, polypropylene (much of it through the Prime Polymer joint venture), phenols, high-purity terephthalic acid (PTA), PET resin, polyurethane feedstocks, industrial chemicals, catalyst licensing, and "green" / sustainable-feedstock initiatives.

The capability here is scale and integration - operating naphtha crackers and downstream derivative units efficiently. The problem is that this is a structurally challenged business in Japan: domestic demand is shrinking, Chinese capacity additions have flooded Asia with cheap polyolefins and chemicals, and naphtha-based crackers are high-cost versus Middle Eastern and US shale-advantaged competitors. B&GM swung to an operating loss in FY2025, hurt by low cracker operating rates and inventory-valuation losses as naphtha prices fell (FY2025 results, 13 May 2026).

Why it exists separately - and why it may not exist inside Mitsui Chemicals much longer: the economics, capital intensity, and decision speed required for commodity petrochemicals are fundamentally different from specialty materials. In May 2025 the company announced it is considering splitting off B&GM by around the end of FY2027 so it can be managed, partnered, and consolidated on a petrochemical-specific basis - including a planned consolidation of western-Japan ethylene production at Mitsui's Osaka complex with industry partners.

Section 3: Products and Business Detail

Vision-care monomers (MR series). These are high-refractive-index resin precursors cast into prescription spectacle lenses. The higher the index (1.60 up to 1.74), the thinner the lens for a given prescription, which is the entire selling point of "ultra-thin" lenses. Mitsui supplies the monomer; lens makers cast, cure, coat, and brand the finished lens. The product is a textbook specialty: small in tonnage, high in value, deeply qualified into customers' processes, and protected by formulation know-how and brand-standard status.

EUV pellicles. A pellicle is a thin, transparent membrane stretched over a frame and mounted above a photomask. It keeps stray particles off the mask's focal plane so defects do not print onto wafers. For EUV lithography this is brutally difficult because EUV light is absorbed by almost everything, so the membrane must be vanishingly thin yet survive enormous thermal load. Mitsui makes these at Iwakuni-Ohtake under exclusive ASML license, was first to commercial production (2021), and is industrialising CNT pellicles with imec for next-generation high-power EUV, with production facilities established at Iwakuni-Ohtake (reported target capacity on the order of 5,000 sheets/year). This is one of the most technically defensible products in the entire company.

ICROS tape. A back-grinding / protective tape used when wafers are thinned during semiconductor packaging. It is a consumable that ships in volume with chip production, so it rides the same semiconductor demand wave as pellicles.

Elastomers (TAFMER) and polypropylene compounds. Olefin-based elastomers that modify the toughness and flexibility of plastics, plus compounded PP grades engineered to automaker specifications. These go into bumpers, trim, under-hood components, packaging films, and wire-and-cable. Value comes from formulation and qualification rather than from the base polymer.

Agrochemicals, oral care, nonwovens, personal care. A cluster of specialty end-products with their own registration and qualification barriers, sold into agriculture, dental, and hygiene markets.

Commodity petrochemicals (B&GM). Ethylene and propylene from naphtha cracking, polyethylene and polypropylene (largely via Prime Polymer), phenols, PTA, PET, polyurethane feedstocks, plus licensing of catalyst and process technology and a "green"/bio- and recycled-feedstock effort. Made at large integrated complexes in Japan; the western-Japan cracker footprint is being rationalised and consolidated at Osaka with industry partners.

Manufacturing and geography. Production is anchored in Japan (Iwakuni-Ohtake for pellicles; Osaka, Omuta, Ichihara and other works for petrochemicals and derivatives) with global manufacturing and sales reach across the Americas (Mitsui Chemicals America), Europe, and the rest of Asia. The specialty domains are increasingly global in their customer base even where production remains Japan-centric. Notable milestones include world-first EUV-pellicle commercial production (2021), the VISION 2030 plan (2021), the imec CNT-pellicle partnership (2023-2024), and the May 2025 announcement to study the B&GM spin-off.

Section 4: Customers

Eyewear / lens makers. Customers are the world's prescription-lens manufacturers - companies such as Hoya, EssilorLuxottica, and Zeiss-affiliated operations. The buying decision sits with the lens maker's R&D and procurement functions, and the criterion is whether the monomer hits the target refractive index, casting behaviour, and coating compatibility their entire product line is built around. The sales cycle is long and the switching cost is high: changing monomer chemistry means requalifying lens designs, casting lines, and coatings. This is why Mitsui holds durable global leadership rather than competing on price each cycle.

Leading-edge chipmakers (via mask shops). EUV pellicles and ICROS tape ultimately serve the handful of companies running EUV lithography - principally TSMC, Samsung, and Intel - usually through their photomask supply chains. The decision-makers are process-integration and lithography engineers who qualify pellicles against transmission, lifetime, and defectivity specs on specific EUV scanners. Qualification is exacting and the installed base of EUV tools is concentrated, so this is a high-value, high-concentration customer set. The flip side is that demand tracks the leading-edge semiconductor capex cycle, which is itself volatile.

Automakers and tier suppliers. Mobility customers are global vehicle OEMs and their tier-1/tier-2 component makers. Buying decisions run through engineering design-in: once a compound is specified into a platform it stays for the model's production life, giving multi-year revenue visibility but exposing the business to auto-production volumes and tariff-driven supply-chain shifts.

Agriculture, hygiene, dental, packaging, construction. The Life & Healthcare and B&GM customers span crop-protection distributors, hygiene-product manufacturers, dental-materials companies, and converters/processors buying bulk polyolefins. Commodity-plastics customers are price-driven and switch readily, which is precisely the structural weakness of B&GM.

Concentration and contract structure. The specialty domains feature qualification-based lock-in and long-term supply relationships (especially lens monomers and semiconductor materials), which supports revenue predictability. The commodity domain is closer to spot/short-term pricing tied to naphtha and regional supply-demand. The semiconductor-materials customer base is concentrated by nature (few EUV operators), which is a quality signal more than a risk while those customers keep expanding leading-edge capacity.

Section 5: Competitive Landscape

Mitsui Chemicals competes in distinct arenas, and its position varies dramatically across them.

In semiconductor pellicles it is one of a small group - Mitsui, Shin-Etsu Chemical, and S&S Tech are cited as collectively holding an estimated 70-80% of the pellicle market - and Mitsui's exclusive ASML EUV-pellicle license plus first-mover commercial status give it a genuinely strong position at the leading edge. The EUV pellicle market itself was estimated at roughly USD 558 million in 2024, projected toward USD 1.6 billion by 2030 (Grand View Research). This is where Mitsui's moat is deepest.

In high-index lens monomers Mitsui is the global leader, with the MR series serving as an industry standard; competition exists (including Korean and Japanese chemistry suppliers) but Mitsui's installed qualification base is the barrier.

In elastomers and polyolefin compounds Mitsui competes with Dow, LyondellBasell, ExxonMobil Chemical, and Asian polyolefin majors; it wins on formulation and auto design-in rather than on commodity cost.

In commodity petrochemicals (B&GM) Mitsui is a high-cost, sub-scale competitor by global standards, pressured by Middle Eastern and US shale-advantaged producers and by Chinese overcapacity. This is the arena where it loses, and the reason for the planned spin-off and the cracker consolidation with Japanese peers.

Barriers to entry are high in pellicles (exclusive license, process know-how, customer qualification) and lens monomers (qualification lock-in, brand-standard status), moderate in elastomers (design-in), and low in commodity plastics (where capital and feedstock cost decide outcomes). The structural shift to watch is the consolidation of Japanese petrochemicals - Mitsui, Mitsubishi Chemical, Asahi Kasei, and Sumitomo Chemical are all rationalising crackers - which should, over time, reduce domestic overcapacity.

Market caps are approximate peer-size references with wide ranges given share-price movement; verify against a live quote before relying on any figure.

Section 6: Industry

Mitsui sits across two very different industries. The specialty-materials side is driven by secular technology demand: the semiconductor leading edge (more EUV layers per advanced node means more pellicles and more consumables), vision correction (a rising global myopia burden and demand for thinner lenses), vehicle electrification and lightweighting (more engineered polymers per car), and hygiene/agriculture demographics. The EUV pellicle market's projected mid-teens CAGR to 2030 is representative of the demand backdrop for the ICT domain. These markets are growing and, in pellicles and lens monomers, supply is concentrated, which supports pricing.

The commodity-petrochemicals side is the opposite story. It is deeply cyclical, tied to the naphtha-to-ethylene spread, regional supply-demand balance, and global GDP. Japanese crackers are structurally disadvantaged: domestic demand is in secular decline, and a wave of Chinese capacity has turned Asia into a chronically oversupplied market for polyolefins and basic chemicals. This is a global rationalisation story - Japanese majors are collectively shutting and consolidating crackers - and it is the central reason Mitsui wants B&GM out of the parent.

Cyclicality therefore differs by domain: ICT rides the semiconductor capex cycle (volatile but secularly up), Mobility rides auto production (cyclical), Life & Healthcare is relatively defensive, and B&GM is the most cyclical and currently the weakest. Regulation matters most in agrochemicals (registration), medical-adjacent materials, and increasingly in carbon/feedstock policy, where the "green" part of B&GM (bio- and recycled feedstocks) is positioned. Tailwinds at the industry level: EUV adoption, myopia and ageing demographics, lightweight-vehicle materials, and Japanese petchem consolidation reducing oversupply. Headwinds: Chinese chemical overcapacity, energy-cost volatility, and trade-policy fragmentation.

Section 7: Growth Triggers

All triggers below are drawn from the six concalls. Numbers in management's quantitative guidance are paraphrased as direction only.

• Semiconductor-materials volume ramp (pellicles + ICROS tape). Management cited recovering semiconductor demand driving ICT volume gains, "particularly pellicles and ICROS tape for cutting-edge applications." Repeated across the Q2 FY2025 (11 Nov 2025) and Q3 FY2025 (5 Feb 2026) calls.

• CNT (carbon-nanotube) pellicles for high-power EUV. Next-generation pellicle technology with imec, with production facilities established at Iwakuni-Ohtake, targeted at the higher-power EUV systems entering leading-edge fabs. (Strategic initiative reiterated in semiconductor commentary, Q2 FY2025, 11 Nov 2025.)

• Elastomer (TAFMER) capacity expansion in Mobility. Management pointed to an elastomer expansion contributing roughly ¥6 billion of volume growth in the Mobility outlook. (Q2 FY2025 call, 11 Nov 2025.)

• Vision care and agrochemicals volume growth in Life & Healthcare. Both cited as volume drivers, with a known temporary drag from the Omuta Works production suspension. (Q2 FY2025, 11 Nov 2025.)

• New coating and engineering-materials plant capacity. Management flagged continuing investment in new coating/engineering-materials plants alongside semiconductor capex. (Q2 FY2025, 11 Nov 2025.)

• B&GM structural improvement. For FY2026, management guided a material improvement in B&GM (a swing of roughly +¥15 billion toward a much smaller loss) from facility consolidation, restructuring, and the absence of one-off inventory effects. (FY2025 results, 13 May 2026.)

"Growth areas expected to reach further business expansion... structural improvements in B&GM, and the elimination of one-time factors." - paraphrased from FY2025 results / FY2026 outlook (13 May 2026).

• Basic & Green Materials spin-off by ~end FY2027. The May 2025 decision to study splitting off the entire commodity-petrochemicals business is the largest structural trigger; it would let the petchem unit pursue green-chemical and consolidation investments on its own cash flow while leaving the parent a specialty company.

"The new entity will enable us to make management decisions that are fast-paced and tailored to the petrochemicals sector, and pursue investments for green chemicals." - spin-off announcement context (May 2025).

• Western-Japan cracker consolidation at Osaka. Consolidation of ethylene production with industry partners to lift utilisation and cut structural cost. (Ongoing restructuring, referenced through FY2025 commentary.)

Section 8: Key Risks

Commodity-petrochemicals losses and naphtha-driven inventory swings. B&GM swung to an operating loss in FY2025, hit by low cracker operating rates and inventory-valuation losses when naphtha prices fell (FY2025 results, 13 May 2026). The mechanism is direct: when naphtha falls, the value of in-process and finished commodity inventory written at higher cost is marked down, and weak Asian demand prevents passing cost through. This is a high-probability, moderate-to-large drag until the spin-off and consolidation take effect.

Middle East / energy disruption. For FY2026 management explicitly built in a roughly ¥15 billion profit hit attributed to the Middle East situation, flowing mainly through B&GM.

"...a loss of approximately 15.0 billion yen is assumed... mainly in B&GM... from decreased sales volume from production cuts and worsening yield/energy efficiency." - paraphrased from FY2025 results / FY2026 outlook (13 May 2026).

The mechanism is feedstock and energy cost plus forced production cuts; it is a live, management-flagged risk rather than a hypothetical.

Semiconductor-cycle and customer concentration in ICT. The crown-jewel ICT products depend on a small set of leading-edge fabs continuing to expand EUV capacity. If the semiconductor capex cycle stalls, pellicle and consumable volumes fall quickly, and the concentration of EUV operators means a single customer's pause is material. This is a moderate-probability, high-amplitude risk for the segment management is counting on most.

Trade policy / tariffs. US tariff policy was cited as roughly a ¥3 billion negative in FY2025, affecting Mobility and exported chemicals (FY2025 results, 13 May 2026). The mechanism is reduced volumes and rerouted auto supply chains; moderate and ongoing.

Spin-off execution risk. Carving out B&GM by ~end FY2027, while consolidating crackers with competitors, is operationally and politically complex (labour, JV partners such as Prime Polymer, asset valuation). If it slips or is structured poorly, the parent keeps absorbing commodity losses longer than expected.

Plant operational reliability. The company has had repeated operational incidents in its heavy assets - an Osaka steam-supply failure flagged in Q1 FY2025 (7 Aug 2025) and prior ethylene-plant failures. Each incident dents utilisation and profit and underscores the fragility of the ageing petrochemical footprint.

FX and yen translation. With Japan-centric production and global sales, currency moves both ways; management cited several billion yen of adverse currency in Mobility in FY2025. Specific rather than generic, but a swing factor rather than a thesis-breaker.

Section 9: Walk the Talk

The six concalls used here: Q3 FY2024 (4 Feb 2025), FY2024 full year (13 May 2025), Q1 FY2025 (7 Aug 2025), Q2/H1 FY2025 (11 Nov 2025), Q3 FY2025 (5 Feb 2026), and FY2025 full year (13 May 2026).

Starting at the oldest, in Q3 FY2024 (Feb 2025) management held its full-year operating-income guidance unchanged and raised the dividend to ¥150 from ¥140, signalling confidence. By the FY2024 results (May 2025) the company landed full-year core operating income close to but modestly below that held guidance, while delivering the promised ¥150 dividend - a small miss on profit, a clean keep on the shareholder-return promise. That set the early pattern: shareholder-return commitments are honoured; profit guidance is reliable on the specialty side and shakier on the commodity side.

Through Q1 FY2025 (Aug 2025) management reported strong specialty performance but flagged the Osaka steam-supply failure as a fresh uncertainty for the second half - an honest, early disclosure of a problem rather than a buried one. Then came the pivotal sequence. On the Q2/H1 FY2025 call (Nov 2025), management was emphatic about hitting its raised full-year target:

"We are determined to achieve this forecast." - CFO commentary, Q2 FY2025 (11 Nov 2025), referring to full-year operating income of ¥110 billion.

Just one quarter later, on the Q3 FY2025 call (Feb 2026), the company cut that full-year operating-income forecast (to ¥103 billion), citing continued weakness in Basic & Green Materials. And at the FY2025 results (May 2026), actual core operating income came in lower again, at ¥100 billion. So a target the CFO said the company was "determined to achieve" in November was walked down twice within six months. The entire shortfall sat in the commodity domain; the specialty domains delivered roughly as guided, with management's claim that specialty margins held "in the 11% range" (Nov 2025) borne out by the resilient FY2025 specialty result.

The pattern is consistent and legible. Management is credible and conservative on the specialty domains, and credible on capital returns (it kept ¥150 dividends and launched a buyback). But it has been repeatedly too optimistic about Basic & Green Materials - guiding recoveries that the cycle and Chinese oversupply then undercut. The forward FY2026 guidance again leans on a large B&GM improvement, so the same skepticism applies: trust the specialty trajectory and the shareholder-return promises; discount the commodity-recovery assumptions until the spin-off changes the structure.

Section 10: Shareholder Friendliness Index

Dividends. Mitsui Chemicals paid ¥140 per share for FY2023 (ended Mar 2024), raised to ¥150 for FY2024 (ended Mar 2025), and held ¥150 for FY2025 (ended Mar 2026) on a pre-split-equivalent basis (¥75 interim + ¥75 year-end), with the 2-for-1 stock split effective 1 January 2026 doubling the share count so future per-share figures restate accordingly. The policy targets a dividend on equity (DOE) of 3.0% or higher and a total return ratio (dividends plus buybacks over net income) of 40% or more from FY2025 onward; FY2024's total return ratio reached 118.8% with a DOE of 3.3%, meaning the company returned well more than its earnings that year - a deliberate, above-earnings return profile rather than a one-off.

Buybacks and dilution. In FY2024 the company bought back stock (treasury shares rose from ~10.7 million to ~13.5 million shares year-on-year), and in February 2026 it launched a larger program: up to ~18.4 million shares (about 4.9% of shares outstanding) for up to ¥30 billion, running February to July 2026, paired with cancellation of treasury stock to take holdings down to about 5% of issued shares. The MoatMap database (covering only the trailing ~90 days) shows that program substantially executed, recording 6,584,000 shares repurchased at about ¥4,556 for roughly ¥30.0 billion, cumulative ~4.90%, by 28 April 2026 - i.e. the ¥30 billion authorisation was effectively used up. With treasury cancellation accompanying the program, the share count is being actively reduced rather than allowed to drift up from dilution. (Recent buyback figures: MoatMap, since ~Mar 2026; older program and dividend history: company IR / financial-results summaries, FY2023-FY2025.)

Verdict: Returns Capital - a multi-year record of rising-then-held dividends above a DOE floor, a total return ratio that exceeded 100% in FY2024, and a ¥30 billion buyback-plus-cancellation in 2026, all backed by an explicit 40%+ total-return-ratio policy.

Section 11: Insider Activities

Source note: Japan (TSE) insider disclosure portals (EDINET 5%-rule large-shareholding reports and TDnet) are gated and not reliably reachable by open search, so the MoatMap cross-market disclosure database (market: JP) is the source for this section. The most recent MoatMap scrape was 2026-06-19 23:00 UTC (about 41 hours before this report); very recent filings may therefore be missing.

Over the trailing 12 months MoatMap records a single reportable transaction, and it is a substantial-shareholder (5%-rule) filing rather than a director or officer dealing:

Reading the signal. This is a 5%-rule large-shareholding report filed by BlackRock Japan's asset-management arm, disclosing aggregate holdings of about 20.8 million shares (5.75% of shares outstanding) held for investment-management purposes across discretionary mandates and investment trusts. It is passive/institutional accumulation crossing a disclosure threshold, not an insider with operating knowledge expressing conviction. Japanese 5%-rule reports also carry no execution price, so size and direction are the only data. There were no open-market purchases or sales by directors or executive officers in the window - the strongest category of insider signal is simply absent here.

Net assessment. With only one filing in twelve months, and that filing a passive institutional 5%-rule report rather than an officer or director trade, there is no meaningful directional insider signal in either direction. The read is neutral: no insider conviction buying to flag, and no insider selling to worry about. Given the stale-scrape caveat above and the gated nature of Japanese disclosure, a more recent director/officer dealing could exist but is not captured here.

Section 12: Scenarios

Bull case. The specialty pivot compounds. EUV adoption deepens at the leading edge, more EUV layers per node lift pellicle and ICROS-tape consumption, and Mitsui's exclusive ASML license plus first-mover CNT pellicles for high-power EUV keep it the default supplier into TSMC, Samsung, and Intel. The elastomer and coating-materials expansions ramp into a recovering auto and electronics market, and the vision-care franchise grows on global myopia and thin-lens demand. Crucially, the Basic & Green Materials spin-off completes around FY2027, the western-Japan cracker consolidation lifts utilisation, and the parent emerges as a clean, higher-margin specialty company no longer dragged down by commodity losses and inventory swings. With the share count shrinking from buybacks and cancellation and a 40%+ total-return policy intact, the business the market sees in two to three years is structurally different and clearly better than the diversified chemical maker of today.

Base case. Management delivers roughly what it has guided. The specialty domains keep growing at mid-single-digit-plus volume rates with margins holding around the low-double-digit range, ICT remains the standout on semiconductor recovery, and Mobility and Life & Healthcare grind forward. Basic & Green Materials improves from its FY2025 trough as restructuring and the absence of one-off inventory hits help, but the recovery is partial and lumpy - the Middle East and energy drag, plus Chinese oversupply, keep it from fully healing before the spin-off. Dividends stay at policy levels and buybacks continue opportunistically. The spin-off study proceeds toward an ~FY2027 separation. The company gradually re-rates as a specialty business, but the commodity overhang and execution timeline keep that re-rating measured rather than dramatic.

Bear case. The commodity domain stays the story for longer than hoped. Chinese petrochemical overcapacity persists, naphtha and energy volatility produce more inventory-valuation losses, and the Middle East disruption proves deeper or longer than the ¥15 billion management penciled in - B&GM keeps bleeding. The spin-off slips or stalls on JV-partner, valuation, or labour complications, leaving the parent absorbing losses past FY2027. Simultaneously, the semiconductor capex cycle cools, and because ICT's customer base is so concentrated, a pause at one or two leading-edge fabs cuts pellicle volumes sharply just as the growth narrative needed them most. A fresh operational incident at an ageing cracker compounds the pressure. In this world the specialty pivot is real but too slow, and the cyclical and structural drags overwhelm it for an uncomfortably long stretch.